Bioline RX Ltd (NASDAQ:BLRX) saw a significant growth in short interest in January. As of January 15th, there was short interest totalling 746,799 shares, a growth of 40.5% from the December 31st total of 531,549 shares, Marketbeat reports. Based on an average daily volume of 417,594 shares, the short-interest ratio is presently 1.8 days.

BLRX has been the topic of several analyst reports. Zacks Investment Research upgraded Bioline RX from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research report on Wednesday, November 18th. Roth Capital reiterated a “buy” rating and set a $7.00 target price on shares of Bioline RX in a research report on Tuesday, January 12th. Finally, Maxim Group reiterated a “buy” rating and set a $4.00 target price on shares of Bioline RX in a research report on Monday, November 16th. Five research analysts have rated the stock with a buy rating, Bioline RX has an average rating of “Buy” and an average price target of $4.40.

Bioline RX (NASDAQ:BLRX) opened at 1.03 on Friday. The stock’s market capitalization is $56.29 million. The stock has a 50 day moving average price of $1.17 and a 200 day moving average price of $1.46. Bioline RX has a 12 month low of $0.85 and a 12 month high of $3.28.

Bioline RX (NASDAQ:BLRX) last issued its quarterly earnings data on Monday, November 16th. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.05. During the same period in the previous year, the business posted ($0.02) EPS. Equities analysts predict that Bioline RX will post ($0.27) EPS for the current fiscal year.

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications.

12 Month Chart for NASDAQ:BLRX

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Bioline RX Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX Ltd and related companies with MarketBeat.com's FREE daily email newsletter.